Skip Navigation

Lotus's Korean subsidiary received approval of the anti-obesity drug Qsymia®

01 August 2019

Specialty pharmaceutical Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, 1795:TT) today that its subsidiary Alvogen Korea Co., Ltd. (Alvogen Korea) received the final approval of the anti-obesity drug Qsymia® (phentermine and topiramate extended-release) from South Korea Ministry of Food and Drug Safety (MFDS). Qsymia® is developed by VIVUS Inc. and is used for the treatment of chronic weight management or weight-related conditions. Alvogen Korea is responsible for regulatory, sales and marketing activities for Qsymia® in Korea.

Lotus General Manager Petar Vazharov says, 

Alvogen Korea has traditionally a strong position in anti-obesity therapies and brand awareness. The approval of Qsymia® is an important upgrade to the existing portfolio and is our response to the increasing competition from a newer generation of anti-obesity products in the Korean market, such as Belviq®, Contrave® and Saxenda®. While Qsymia is clinically demonstrated to deliver superior weight loss results comparing to current mainstream therapies, it also allows lower dosing burden to patients. The product is approved by USFDA for years and is safe for long term use. As we are celebrating the approval, our team is Korea is actively preparing for the product launch.

Petar Vazharov

Lotus General Manager